“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
BEIJING, 25 September (Reuters) – An experimental coronavirus vaccine developed through China’s Clover biopharmaceuticals appears to be able to trigger immune responses in animal testing, the researchers said.
The result of the monkey test comes months after Clover began an early-stage human trial in Australia in June, as global drug brands rush to expand an effective vaccine that can protect others from the COVID-19 pandemic that has killed nearly a million others.
Clover’s candidate vaccine, which is funded in component through a global coalition of vaccine studies, uses adjuvants, ingredients that can stimulate immune response, GlaxoSmithKline of Britain and US company Dynavax Technologies.
Two doses of the candidate with levels of GSK adjuvant-induced antibodies in monkeys that are higher than those observed in the blood of patients recovering from COVID-19, clover researchers and other Chinese institutes said in an article published Thursday before peer review. : //bit. ly/365RysT
The grades of antibodies activated through two doses of the dynavax adjuvant vaccine, plus alum, were those observed in the serum of convalescent patients, they said.
Adjuvants can simply decrease the amount of antigen, the substance that triggers immune responses, required in the vaccine dose, allowing brands to produce more doses.
The candidate, called S-Trimmer, did not cause a progressive effect of the disease when tested in monkeys, a situation in which the immunity generated through the vaccine aggravates the disease by preventing subjects from getting sick, which experts say can lead to vaccines opposed to coronaviruses.
Vaccinated animals gave the impression that it was from weight loss, fever and organ injuries when they faced the virus after inoculation, according to the study.
No candidate vaccine has been shown to be effective and protect humans from coronavirus, but at least nine applicants are in the latter stages of clinical trials to check their efficacy and quality (report through Roxanne Liu and Tony Munroe in Beijing; editing through Miyoung Kim and Raju Gopalakrishnan)